Translate this page into:
Herpes zoster complicating bortezomib therapy
*For correspondence: hematpgi@gmail.com
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
A 62 year old female patient with multiple myeloma was on follow up in the Haematology clinic, department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, and was receiving bortezomib based chemotherapy given on days 1, 4, 8, and 11 of 35-day cycle. After two such cycles in June 2013, she started developing painful skin lesions on right D9-10 dermatome. On examination erythematous, crusted superficial erosions with a few vesicular lesions were present (Figs A, B). Tzanck smear showed multinucleated giant cells confirming the diagnosis of herpes zoster (Figs C, D). It was found that despite advice she did not take acyclovir prophylaxis during chemotherapy which led to this complication. She was given oral valganciclovir 1 g thrice a day for 10 days. Unfortunately, she was lost to follow up. There are theories which explain increased susceptibility of patients on bortezomib to herpes infection12. Considering two earlier studies34 and our case, it is emphasised that acyclovir prophylaxis should be used during bortezomib treatment.
-
A, B. Well defined erythematous, crusted erosions with a few vesicular lesions (indicated by black arrows in (B) in a linear pattern over the right D 9-10 dermatome. Figs C, D. Light microscopy using tzanck smear and stained with Wright-Giemsa stain showing giant cells.
References
- Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012;10:155-9.
- [Google Scholar]
- Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593-9.
- [Google Scholar]
- Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115:229-32.
- [Google Scholar]
- Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study. Jpn J Clin Oncol. 2011;41:876-81.
- [Google Scholar]
